Novelix Pharmaceuticals boosts capital after warrant conversion

Novelix Pharmaceuticals Limited announced the allotment of 1,074,000 equity shares following the conversion of an equal number of warrants. The allotment, approved by the board of directors on December 24, 2025, was made at an issue price of ₹20 per share, including a premium of ₹10. This preferential issue was made to both promoter and non-promoter warrant holders.

The company received ₹16,110,000 from this conversion, which represents the remaining 75% of the issue price for the 1,074,000 warrants. The warrants were originally allotted on January 10, 2025.

As a result of this allotment, Novelix Pharmaceuticals' paid-up equity capital has increased from ₹161,410,000 (161,410,000 equity shares) to ₹172,150,000, now consisting of 172,150,000 equity shares of ₹10 each. Key allottees include Narahari Belide (100,000 shares), Chintalapati Sesha Sai Nikhil (492,000 shares), KS Swetha (382,000 shares), and Palakurthi Rakesh (100,000 shares).